Secor Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Secor Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-8,927	Closed	-$637K	–	523
2018 Q4	$637K	Buy	8,927 +1,876	+27%	+$180K	0.08%	282
2018 Q3	$867K	Buy	+7,051	New	+$800K	0.09%	265
2018 Q1	–	Sell	-19,607	Closed	-$1.52M	–	598
2017 Q4	$1.52M	Buy	+19,607	New	+$1.34M	0.06%	234
2017 Q2	–	Sell	-72,270	Closed	-$3.13M	–	539
2017 Q1	$3.13M	Buy	72,270 +681	+1%	+$29.2K	0.34%	89
2016 Q4	$2.77M	Buy	71,589 +66,447	+1,292%	+$3.01M	0.34%	85
2016 Q3	$260K	Buy	+5,142	New	+$256K	0.03%	448
2014 Q3	–	Sell	-32,877	Closed	-$488K	–	356
2014 Q2	$488K	Buy	32,877 +11,840	+56%	+$167K	0.26%	137
2014 Q1	$339K	Buy	+21,037	New	+$360K	0.17%	219

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Secor Capital Advisors's NBIX Position: Q1 2019 in Review

Secor Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 8,927 shares — an estimated $637K sold.

Secor Capital Advisors first reported a position in NBIX in Q1 2014 and held it in 8 quarters. The position peaked at $3.13M in Q1 2017. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

Secor Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 8,927 Neurocrine Biosciences shares in Q1 2019, an estimated $637K.
Secor Capital Advisors first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 8 quarters.
Secor Capital Advisors's Neurocrine Biosciences position peaked at $3.13M in Q1 2017.
325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.